BioSpace News Archive

Clearside Biomedical, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Arbutus Biopharma Corporation today reports its third quarter 2022 financial results and provides corporate updates.

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three and nine months ended September 30, 2022.

Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer.

InflaRx N.V. today announced that it has dosed its first healthy volunteer in a randomized, double-blind, placebo-controlled Phase I trial of orally administered, small molecule C5aR inhibitor INF904.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Crescita Therapeutics Inc. today reported its financial results for the third quarter ended September 30, 2022 (“Q3-F2022”).

Vericel Corporation today reported financial results and business highlights for the third quarter ended September 30, 2022.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced the Company will present in person at the following investor conferences in November:

Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).